Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone app aims to help black smokers with HIV kick the habit

NCT ID NCT05709002

Disease control Sponsor: University of Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a mobile app designed specifically for Black adults living with HIV who smoke daily. The app includes culturally tailored content and anxiety-reduction techniques to support quitting. Participants are randomly assigned to use either the tailored app or a standard quit-smoking app, and their progress is tracked with a smartphone-connected breathalyzer to confirm abstinence. The goal is to see if a personalized digital tool can improve quit rates in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile app (MASP+)
What this could lead to
If effective, this app could provide a scalable, tailored tool to help Black smokers with HIV quit, reducing smoking-related health disparities.
What could go wrong
This is a small early-stage trial (76 participants), so results may not apply broadly. The app's success depends on user engagement and may not outperform standard quit-smoking apps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

76 people

The number who actually took part.

Started

Oct 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV-infection (via self-report and picture of medication, lab tests, or diagnosis) * 18+ years of age * Self-identify as Black / African American * Daily smoking (minimum of 10 cigarettes per day on average for at least 2 years) * Motivated to quit smoking (≥ 5 on a 10-point scale) * Willingness to discontinue cigarette use two weeks after baseline visit. * English literacy (score of 4 or greater on REALM-SF) * Moderate to high anxiety sensitivity (score of 5 or greater on SSASI) * Provide a current picture of their cigarette package to verify smoking status * Willing to complete all study surveys/assessments * Agree to use nicotine replacement medications (NRT; nicotine patch and lozenges) * Agree to attempt to quit smoking two weeks after completion of the baseline survey and receipt of study materials Exclusion Criteria: * Actively receiving (ongoing) pharmacotherapy or psychotherapy directly focused on the treatment of smoking cessation, and/or substance use, not provided by the study * Non-fluent/limited English proficiency * Self-reported pregnancy or intentions to become pregnant in near future * Legal status that would interfere with participation * Being non-Black * Cognitive impairment (assessed via the 6-item Cognitive Impairment Test)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cigarette smoking are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cigarette Smoking HIV infectious disease Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cigarette smoking

Contacts and locations

Locations

  • Thomas Street at Quentin Mease Health Center

    Houston, Texas, 77004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.